During the past decade, Istituto Oncologico Veneto conducted 180 clinical trials. In the 10-year time frame, 180 clinical trials started and 41 clinical trials were completed, i.e. on average, 22.8% percent of trials that started reached the finish line to date. In the past 5 years, 97 clinical trials started and 32 clinical trials were completed. i.e. 33% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Istituto Oncologico Veneto" #1 sponsor was "National Cancer Institute, Naples" with 14 trials, followed by "Bristol-Myers Squibb" with 13 trials sponsored, "Istituto Oncologico Veneto IRCCS" with 11 trials sponsored, "Hoffmann-La Roche" with 10 trials sponsored and "Eli Lilly and Company" with 10 trials sponsored. Other sponsors include 184 different institutions and companies that sponsored additional 88 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Istituto Oncologico Veneto" #1 collaborator was "AstraZeneca" with 8 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 8 trials as a collaborator, "Merck Sharp & Dohme LLC" with 8 trials as a collaborator, "Hoffmann-La Roche" with 6 trials as a collaborator and "PharmaMar" with 6 trials as a collaborator. Other collaborators include 116 different institutions and companies that were collaborators in the rest 98 trials.

According to Clinical.Site data, the most researched conditions in "Istituto Oncologico Veneto" are "Metastatic Colorectal Cancer" (13 trials), "Breast Cancer" (12 trials), "Melanoma" (12 trials), "Ovarian Cancer" (7 trials) and "Metastatic Breast Cancer" (5 trials). Many other conditions were trialed in "Istituto Oncologico Veneto" in a lesser frequency.

Most popular intervention types in "Istituto Oncologico Veneto" are "Drug" (205 trials), "Other" (20 trials), "Biological" (18 trials), "Procedure" (9 trials) and "Radiation" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (24 trials), "Gemcitabine" (17 trials), "Nivolumab" (15 trials), "Atezolizumab" (13 trials) and "Capecitabine" (12 trials). Other intervention names were less common.

The vast majority of trials in "Istituto Oncologico Veneto" are 214 trials for "All" genders, 28 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Istituto Oncologico Veneto". 1 are not yet recruiting, 60 are recruiting, 67 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 63 completed trials in Istituto Oncologico Veneto, undefined suspended trials, and 22 terminated clinical trials to date.

Out of the total trials that were conducted in Istituto Oncologico Veneto, 16 "Phase 1" clinical trials were conducted, 95 "Phase 2" clinical trials and 103 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 8 trials that are defined as “Not Applicable".

Istituto Oncologico Veneto has several departments that took part in Clinical trials: "IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Prima" - 15 trials, "IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II" - 41 trials, "U.O.C. Oncoematologia - Istituto Oncologico Veneto Irccs, Presidio Ospedaliero S. Giacomo Apostolo" - 3 trials, "Istituto Oncologico Veneto IOV - IRCCS Unità Operativa Complessa Oncologia Medica 1" - 2 trials